GPC Biotech Schedules Conference Call on August 8th to Discuss First Half 2007 Financial Results
August 02 2007 - 6:05AM
PR Newswire (US)
MARTINSRIED/MUNICH, Germany, Aug. 2 /PRNewswire-FirstCall/ --
PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC;
TecDAX index; Nasdaq: GPCB) today announced that it will hold a
conference call on Wednesday, August 8, 2007 to discuss its
financial results for the first half of 2007. The results will be
published on August 8th in advance of the call. Participants may
listen via live webcast, accessible through the GPC Biotech Web
site at http://www.gpc-biotech.com/, or via telephone. A replay
will be available via the Web site following the live event. The
call, which will be conducted in English, will be held on August 8
at 14:00 CET/8:00 AM ET. The dial-in numbers for the call are as
follows: European participants: 0049-(0)69-5007-1305 or
0044-(0)20-7806-1950 U.S. participants: 1-718-354-1385 About GPC
Biotech GPC Biotech AG is a publicly traded biopharmaceutical
company focused on discovering, developing and commercializing new
anticancer drugs. GPC Biotech's lead product candidate satraplatin
is currently in a Phase 3 registrational trial in second-line
hormone-refractory prostate cancer. GPC Biotech is also developing
a monoclonal antibody with a novel mechanism-of- action against a
variety of lymphoid tumors, currently in Phase 1 clinical
development, and has ongoing drug development and discovery
programs that leverage its expertise in kinase inhibitors. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany) and has
a wholly owned U.S. subsidiary headquartered in Princeton, New
Jersey. For additional information, please visit GPC Biotech's Web
site at http://www.gpc-biotech.com/. This press release contains
forward-looking statements, which express the current beliefs and
expectations of the management of GPC Biotech AG. Such statements
are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could
cause future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors,
and we caution investors not to place undue reliance on the
forward- looking statements contained in this press release. In
particular, there can be no guarantee that additional information
relating to the safety, efficacy or tolerability of satraplatin may
be discovered upon further analysis of data from the SPARC trial or
analysis of additional data from other ongoing clinical trials for
satraplatin. Furthermore, we cannot guarantee that satraplatin will
be approved for marketing in a timely manner, if at all, by
regulatory authorities nor that, if marketed, satraplatin will be a
successful commercial product. We direct you to GPC Biotech's
Annual Report on Form 20-F for the fiscal year ended December 31,
2006 and other reports filed with the U.S. Securities and Exchange
Commission for additional details on the important factors that may
affect the future results, performance and achievements of GPC
Biotech. Forward-looking statements speak only as of the date on
which they are made and GPC Biotech undertakes no obligation to
update these forward-looking statements, even if new information
becomes available in the future. Satraplatin has not yet been
approved by the FDA in the U.S., the EMEA in Europe or any other
regulatory authority and no conclusions can or should be drawn
regarding its safety or effectiveness. Only the relevant regulatory
authorities can determine whether satraplatin is safe and effective
for the use(s) being investigated. DATASOURCE: GPC Biotech CONTACT:
Martin Braendle, Director, Investor Relations & Corporate
Communications, +49 (0)89 8565-2693, , or In the U.S., Laurie
Doyle, Director, Investor Relations & Corporate Communications,
+1-781-890-9007, ext. 267, , both of GPC Biotech Web site:
http://www.gpc-biotech.com/
Copyright